EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average, strong compound growth.
Left:
||||
Year-over-year research & development expense growth
Latest
105.57%
↑ 211% above average
Average (9y)
33.94%
Historical baseline
Range
High:105.57%
Low:-5.01%
CAGR
+16.7%
Consistent expansion
| Period | Value |
|---|---|
| 2024 | 105.57% |
| 2023 | 30.26% |
| 2022 | 74.18% |
| 2021 | 63.57% |
| 2020 | 13.38% |
| 2019 | -5.01% |
| 2018 | 8.72% |
| 2017 | 3.47% |
| 2016 | 18.97% |
| 2015 | 26.27% |